EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 592 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DZD1516
CAS:DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in bothFórmula:C28H27F2N7O3Pureza:98%Forma y color:SolidPeso molecular:547.56EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Fórmula:C33H37ClN8O3Pureza:98%Forma y color:SolidPeso molecular:629.15BGB-102
CAS:<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Fórmula:C22H25BrN4O2Pureza:99.02%Forma y color:SolidPeso molecular:457.36(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Fórmula:C16H14N2O2Forma y color:SolidPeso molecular:266.29EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97EGFR/CSC-IN-1
CAS:EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potentialFórmula:C54H54Cl2FN7O7S2Pureza:98%Forma y color:SolidPeso molecular:1067.08Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Fórmula:C42H51N9O5Forma y color:SolidPeso molecular:761.91EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Fórmula:C34H39ClFN7O2Pureza:98%Forma y color:SolidPeso molecular:632.17EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Fórmula:C16H9ClIN3Forma y color:SolidPeso molecular:405.62JND3229
CAS:<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Fórmula:C33H41ClN8O2Pureza:98.75%Forma y color:SolidPeso molecular:617.18EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Fórmula:C27H36N8O3Peso molecular:520.63EGFR-IN-36
CAS:EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).Fórmula:C26H25ClN6O2Forma y color:SolidPeso molecular:488.97Simotinib
CAS:Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.Fórmula:C25H26ClFN4O4Pureza:99.7%Forma y color:SolidPeso molecular:500.95Lifirafenib
CAS:Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFórmula:C25H17F3N4O3Pureza:97.99% - 98%Forma y color:SolidPeso molecular:478.42HKI-357
CAS:<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Fórmula:C31H29ClFN5O3Pureza:99.91%Forma y color:SolidPeso molecular:574.05HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Forma y color:SolidPeso molecular:503.6EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Fórmula:C28H33BrN7O2PForma y color:SolidPeso molecular:610.49JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Forma y color:SolidPeso molecular:488.35EGFR-IN-1
CAS:<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Fórmula:C28H30N6O4Pureza:98%Forma y color:SolidPeso molecular:514.58EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Fórmula:C32H28BrF3N6O4SForma y color:SolidPeso molecular:729.572′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Forma y color:SolidPeso molecular:283.31PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Fórmula:C19H22ClN7O3Pureza:98%Forma y color:SolidPeso molecular:431.88Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Forma y color:SolidPeso molecular:484.93EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Fórmula:C28H33N7O2Pureza:98.64%Forma y color:SolidPeso molecular:499.61BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Fórmula:C24H31N5O4Pureza:96.74%Forma y color:SolidPeso molecular:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Fórmula:C23H15ClFN3OS2Pureza:98.93%Forma y color:SolidPeso molecular:467.97EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Fórmula:C28H31ClN6O4Pureza:99.16%Forma y color:SolidPeso molecular:551.04EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PForma y color:SolidPeso molecular:568.01HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Fórmula:C28H26F3N7O3Forma y color:SolidPeso molecular:565.55EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Fórmula:C31H30FN7OForma y color:SolidPeso molecular:535.61EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OForma y color:SolidPeso molecular:514.58EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Fórmula:C16H15N3OSForma y color:SolidPeso molecular:297.375EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Fórmula:C27H19ClFN3OForma y color:SolidPeso molecular:455.91EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Fórmula:C37H47N9O3Forma y color:SolidPeso molecular:665.83PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Fórmula:C25H25N7O2Forma y color:SolidPeso molecular:455.51HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Fórmula:C19H31NO6SForma y color:SolidPeso molecular:401.52EGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Fórmula:C13H13N5OForma y color:SolidPeso molecular:255.275EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Fórmula:C19H21N3O2SForma y color:SolidPeso molecular:355.45HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SForma y color:SolidPeso molecular:394.447EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Fórmula:C26H27ClN6O2Forma y color:SolidPeso molecular:490.98HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Fórmula:C15H12N2O4Forma y color:SolidPeso molecular:284.27EG31
CAS:<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Fórmula:C30H13Br2N3O6Forma y color:SolidPeso molecular:671.25EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Fórmula:C26H28ClN3O4Forma y color:SolidPeso molecular:481.97Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Fórmula:C32H31ClN6O4Forma y color:SolidPeso molecular:599.08Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Fórmula:C31H36N8O3Forma y color:SolidPeso molecular:568.669SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Forma y color:SolidPeso molecular:482.96ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Forma y color:SolidPeso molecular:528.53BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08Neptinib
CAS:<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Fórmula:C22H23ClFN5O2Forma y color:SolidPeso molecular:443.90EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Fórmula:C33H28N6O3SForma y color:SolidPeso molecular:588.68EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Forma y color:SolidHER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Fórmula:C17H18BrN5O2SForma y color:SolidPeso molecular:436.33EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Fórmula:C27H25ClN2O4Forma y color:SolidPeso molecular:476.951EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Fórmula:C25H24ClN7O2Forma y color:SolidPeso molecular:489.96EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Fórmula:C16H16N4O2SForma y color:SolidPeso molecular:328.39Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Fórmula:C10H8N2OForma y color:SolidPeso molecular:172.183Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Fórmula:C24H24Br2ClN9O3Pureza:99.52%Forma y color:SolidPeso molecular:681.77EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Fórmula:C30H35FN6O3Forma y color:SolidPeso molecular:546.64EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Forma y color:SolidNSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Fórmula:C20H16O7Forma y color:SolidPeso molecular:368.34HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Forma y color:SolidPeso molecular:504.58Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SForma y color:SolidPeso molecular:663.59LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Fórmula:C21H20ClN3O4Forma y color:SolidPeso molecular:413.854EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Fórmula:C27H31N7O3Forma y color:SolidPeso molecular:501.58EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Forma y color:SolidEGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Fórmula:C27H29F2N7O3Forma y color:SolidPeso molecular:537.56NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Fórmula:C28H30Cl2F2N6O4Forma y color:SolidPeso molecular:623.48D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Fórmula:C25H26Cl2FN7O3Forma y color:SolidPeso molecular:562.42EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SForma y color:SolidPeso molecular:519.57EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Fórmula:C12H14N4OS2Forma y color:SolidPeso molecular:294.4EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Forma y color:SolidPeso molecular:567.45JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Fórmula:C31H29FN4O3SForma y color:SolidPeso molecular:556.65EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Forma y color:SolidPeso molecular:370.37EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Forma y color:SolidPeso molecular:694.6HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Forma y color:Odour LiquidNimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Forma y color:LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFórmula:C16H15N5Forma y color:Yellow SolidPeso molecular:277.331Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFórmula:C26H26N6O2SPureza:99.14%Forma y color:SolidPeso molecular:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Pureza:95%Forma y color:LiquidRef: TM-T80604
Producto descatalogadoEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Fórmula:C32H41BrN9O2PPureza:98%Forma y color:SolidPeso molecular:694.6Ref: TM-T78788
Producto descatalogadoYK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Fórmula:C27H32N8O2Pureza:98%Forma y color:SolidPeso molecular:500.6Ref: TM-T79461
Producto descatalogadoEGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Fórmula:C19H20N4O3Forma y color:SolidPeso molecular:352.39Ref: TM-T200157
Producto descatalogadoEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Fórmula:C24H27F3N6OForma y color:SolidPeso molecular:472.51Ref: TM-T200485
Producto descatalogado
